NeoImmuneTech (A950220) Q2 2025 earnings summary

Executive summary

• Focuses on T cell-based immunotherapy R&D, with NT-17 as the lead pipeline in oncology and non-oncology indications, including ARS and various cancers.

• No commercial product sales yet; revenue generated from research services and licensing opportunities.

• Significant ongoing clinical trials and global partnerships, including with Merck and Roche for combination therapies.

• Company listed on KOSDAQ since 2021, with 21.18% held by the largest shareholder.

Financial highlights

• H1 2025 revenue: $26,690, down from $124,917 in FY2024.

• Operating loss for H1 2025: $(10,329,712); net loss: $(10,810,221).

• Cash and cash equivalents at June 30, 2025: $15.1M, down from $23.2M at year-end 2024.

• Accumulated deficit: $232.1M as of June 30, 2025.

• R&D expenses for H1 2025: $7.1M (consolidated), $7.4M (separate), representing over 26,000% of sales due to minimal revenue.

Outlook and guidance

• Management highlights ongoing efforts to secure licensing deals and government contracts, especially for ARS.

• A capital increase is planned for September 2025 to address liquidity concerns.

• Continued focus on advancing clinical trials and expanding indications for NT-17 and other pipeline assets.